Overview
Granules India manufactures Active Pharmaceutical Ingredients, Pharmaceutical Formulation Intermediates, and Finished Dosages for customers in more than 80 countries, leveraging large-scale, cost-efficient production. Its vertical integration means it controls the production chain from base chemicals to final packaged medicines, while also marketing its own label products in the US via Granules Pharmaceuticals Inc. The company differentiates itself through a global manufacturing footprint, scale, and an integrated supply chain that supports both contract manufacturing and branded products, including advanced areas like MUPS, oncology, and peptide therapeutics. Its goal is to provide globally accessible, affordable medicines by maintaining secure supply and expanding capabilities in complex therapies, while pursuing sustainability through green chemistry and net-zero emissions.
Work here?Claim your company
Simplify's take
What believers are saying
- Q2 FY27 revenue rose 20.3% and profit jumped nearly 40% on November 2, 2026.
- North America drove 72% of revenue, anchoring growth with strong U.S. demand.
- Five U.S. launches are lined up across the next two quarters, expanding controlled-substance sales.
What critics are saying
- Gagillapur received 11 FDA observations on October 30, 2026, extending the February 2025 Warning Letter.
- Incyte sued Granules on November 4-5, 2026 over ruxolitinib extended-release tablets in Texas and New Jersey.
- Patent fights on Jakafi XR and FDA remediation can delay launches, cash flows, and management attention.
What makes Granules unique
- Granules controls APIs, PFIs, and dosages, compressing costs across the stack.
- It shipped about one-third of global paracetamol and served 80-plus countries in 2026.
- Its U.S. subsidiary won 2026 tentative approvals with 180-day exclusivity on amphetamine generics.
Help us improve and share your feedback! Did you find this helpful?